RESOLVING THE LEDGER
This is one outlet's own report from Quartz — the article as it was filed. Other outlets are covering the same event; open the full story to compare every source side by side.
See the full story · 7 sources
Merck $MRK and Moderna $MRNA announced Wednesday that their personalized mRNA-based cancer vaccine, combined with Merck 's immunotherapy Keytruda, met the primary and a key secondary endpoint in a pivotal Phase 3 trial for patients with surgically removed high-risk melanoma — the first positive Phase 3 result for an individualized neoantigen therapy and for any mRNA-based cancer treatment.
AIPROPX is an independent multi-source news index — we track, compare, and connect coverage from across the web into one place you won't find anywhere else.